Sign in Create account

Jagsonpal Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: JAGSNPHARM BSE: 507789
₹237.74
▲ 3.03 (1.29%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
3/100
Expensive
Momentum
85/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹1,565 Cr
PE (TTM)
35.0
Industry median 36.1 (152 companies)
Price to Book
5.7
PEG (TTM)
-0.8
Institutions holding %
2.92%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
5.6
Relative return vs Sector, qtr %
-0.1
Free Cash Flow
₹47 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
25.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-25.24%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
3.87%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
22.18%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
8.76%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
5.06
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
60.28
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
16.04%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
21.81%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
21.03%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
13.60%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
20.30%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
15.60%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (15.6%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.3%
Low 232.0000 · High 246.0000
1W return
5.4%
Low 226.7600 · High 251.0000
1M return
-1.3%
Low 217.8100 · High 251.0000
52W return
6.9%
Low 155.0000 · High 264.5000
Lifetime High ₹761.2000 (Nov. 29, 2024)
Lifetime Low ₹6.3500 (Oct. 28, 2008)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
237.0
10D
235.5
20D
234.7
50D
232.1
100D
224.0
200D
205.2

Delivery and volume

Day avg. delivery
55.1%
Week avg. delivery
41.7%
Month avg. delivery
16.4%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

238.58
Pivot
First resistance245.16
Second resistance252.58
Third resistance259.16
First support231.16
Second support224.58
Third support217.16
Day RSI53.9
Day MFI92.1
Day MACD0.79
Day MACD signal0.06

Beta

1M-0.88
3M0.59
1Y0.51
3Y1.11

Price change analysis

↓ -1.3%
Over 1 Month
LowHigh
217.81251.00
↓ -0.1%
Over 3 Months
LowHigh
214.24263.70
↑ 28.1%
Over 6 Months
LowHigh
184.00264.50
↑ 6.9%
Over 1 Year
LowHigh
155.00264.50
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 35.0 (own history: 18.2–49.7)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹82 Cr
Net profit (June 30, 2026)
₹13 Cr
Basic EPS (June 30, 2026)
₹2.0000

Ranks #84 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter69.05%
  • FII/FPI2.30%
  • Other DII0.62%
  • Public28.03%

Largest holders

NameCategoryShares %Shares
Aresko Progressive Private Limited (Trustee of Aresko Progressive Trust, a in the capacity of representative partner of J&P Investments Partnership)Promoter20.2600%13335635
INFINITY CAPITAL (Formerly Infinity Holdings Sidecar1)Promoter18.0600%11888250
INFINITY HOLDINGSPromoter16.7600%11032550
INFINITY PORTFOLIO HOLDINGSPromoter8.6900%5717950
RAJPAL SINGH KOCHHARPromoter4.6000%3030400

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 69.36% to 69.05% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 2.46% to 2.30% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.00% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 140 insider trades, 10 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
29 Jun 2022 ARESKO PROGRESSIVE PRIVATE LIMITED Promoter Sell 0 ₹0
28 Feb 2022 ARESKO PREGRESSIVE PVT. LTD. As partner J & P Investments Partnership Promoter group Sell 0 ₹0
25 Feb 2022 ARESKO PREGRESSIVE PVT. LTD. As partner J & P Investments Partnership Promoter group Sell 0 ₹0
4 Jan 2021 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0
24 Dec 2020 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0
23 Dec 2020 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0
21 Dec 2020 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0
18 Dec 2020 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0
15 Dec 2020 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0
15 Dec 2020 INDERPAL SINGH KOCHHAR Immediate relative Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 107 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
24 Sep 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 423,870 241.2000 NSE
24 Sep 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 423,870 241.0300 NSE
24 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Sell 331,971 242.7400 NSE
24 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Buy 331,971 242.6000 NSE
24 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Sell 331,971 242.7400 NSE
24 Sep 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 423,870 241.2000 NSE
24 Sep 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 423,870 241.0300 NSE
24 Sep 2026 BLITZQUANT RESEARCH LLP Bulk Buy 331,971 242.6000 NSE
30 Jul 2026 SILVERLEAF CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 412,356 250.4300 NSE
30 Jul 2026 SILVERLEAF CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 412,356 250.6100 NSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 4.0000 — —

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
29 Jul 2026 Financial Results Yes
27 Apr 2026 Financial Results/Dividend Yes
12 Mar 2026 Buyback —
21 Jan 2026 Financial Results Yes
3 Nov 2025 Financial Results Yes

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Company Update Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
30 Sep 2026 Company Update Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Sep 2026 Company Update Jagsonpal Pharmaceuticals Ltd - 507789 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
25 Sep 2026 Insider Trading / SAST Jagsonpal Pharmaceuticals Ltd - 507789 - Closure of Trading Window
21 Sep 2026 AGM/EGM Jagsonpal Pharmaceuticals Ltd - 507789 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
18 Sep 2026 AGM/EGM Jagsonpal Pharmaceuticals Ltd - 507789 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (60.3x)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Jagsonpal Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.